Original Publication Date: 21 November, 2013
Publication / Source: Clinical Practice
Authors: Junji Furuse
Since gemcitabine was first established as a standard treatment for unresectable pancreatic cancer in the 1990s, various chemotherapeutic regimens for pancreatic cancer have been investigated in Phase III studies. However, few chemotherapeutic regimens have demonstrated superior survival benefits over gemcitabine; as such, gemcitabine has been recommended as the first-choice treatment agent for a long time.